• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

Next Generation of HIV Antiretrovirals Will Help Drive the HIV Drug Market to More Than $10 Billion in 2015

Posted on: Thursday, 4 May 2006, 12:04 CDT

WALTHAM, Mass., May 4 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, forecasts that the next wave of HIV antiretrovirals will drive the HIV drug market to new heights. According to the new report entitled Human Immunodeficiency Virus, new premium-priced products with greater potency, activity against HIV resistant to current drugs, higher barrier to resistance, and/or improved convenience from both conventional and emerging drug classes will target the span of patients undergoing treatment thus fueling a general expansion of the HIV market, to more than $10 billion in 2015.

The report also finds that the integrase inhibitors and CCR5 antagonists, with Merck, Gilead, and Pfizer products in advanced development, can address major clinical needs and represent significant commercial promise. Additionally, the collaboration between BMS and Gilead to yield a two-class, triple molecule, one pill, once-daily, coformulated product will improve patient compliance because of its convenience and simplicity of administration.

"Interviewed physicians are excited that the new simplified, once-daily, fixed-dose combination of three highly potent and well tolerated antiretrovirals will lead to better regimen adherence, which is essential to prevent resistance emergence in primary management HIV patients," says Sylvia Eash, Ph.D., analyst at Decision Resources.

HIV -- A Favorable Arena for Drug Development

Because HIV is a life-threatening disease, a number of regulatory provisions are in place to expedite the approval of HIV antiretrovirals, thus shortening the time for drug development. Additionally, clinically meaningful data on the antiviral efficacy and the further therapeutic/commercial potential of drug candidates are obtained in a relatively short amount of time (in 10- to 14-day studies) as a result of the availability of well-established and relatively predictive, surrogate end points. However, the maturity of the market is also creating higher hurdles for new entrants: the current and future market is significantly more demanding than it was in the earlier days of the HIV epidemic.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., (http://www.decisionresources.com/) is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact: Elizabeth Marshall Decision Resources, Inc. 781-296-2563 emarshall@dresources.com

Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc., +1-781-296-2563,emarshall@dresources.com

Web site: http://www.decisionresources.com/

Source: PRNewswire

More News in this Category